Recent events
Recent events tied to this brand in public sources.
Back to profile95 entries · Page 4 of 5
2020
U.S. government expands cooperation with AstraZeneca on COVID-19 antibody
The U.S. government expanded its cooperation with AstraZeneca to develop and produce a monoclonal antibody intended to prevent COVID-19. The government said it would invest about $486 million to develop and provide up to 100,000 doses of AstraZeneca's experimental COVID-19 antibody combination.
2020
AstraZeneca releases vaccine trial protocols amid safety concerns
AstraZeneca released details of its coronavirus vaccine trials amid pressure for greater transparency. The article reports that serious neurological illnesses in two trial participants had prompted pauses in the trials; the company said the illnesses were unlikely to be associated with the vaccine or that evidence was insufficient to determine whether they were related.
2020
AstraZeneca acquired Dogma Therapeutics’ oral PCSK9 inhibitor programme
AstraZeneca acquired Dogma Therapeutics’ preclinical oral PCSK9 inhibitor programme for an undisclosed price. Dogma was also eligible for downstream payments tied to regulatory and commercial milestones.
2020
AstraZeneca agrees to acquire global rights to Dogma’s oral PCSK9 project
Dogma Therapeutics and AstraZeneca announced an agreement for AstraZeneca to acquire the global rights to Dogma’s oral PCSK9 project. AstraZeneca will pay an upfront amount and additional payments upon global regulatory and commercial milestones.
2020
Michigan Medicine and AstraZeneca partner on COVID-19 vaccine trials
Michigan Medicine announced that it is partnering with AstraZeneca to bring phase 3 clinical trials to test a COVID-19 vaccine.
2020
AstraZeneca partners with World Heart Federation on cardiovascular disease
AstraZeneca announced a partnership with the World Heart Federation to advance global action to prevent, control and reduce cardiovascular disease and its associated risks and complications.
2020
AstraZeneca launches Spotlight On Heart Failure campaign
AstraZeneca launched the Spotlight On Heart Failure campaign with support from the World Heart Federation. The campaign aims to raise awareness of heart failure signs and symptoms and encourage healthcare professionals to discuss the condition with at-risk patient groups.
2020
Australia and AstraZeneca sign a COVID-19 vaccine cooperation letter
The Australian government and AstraZeneca signed a letter of intent covering COVID-19 vaccine development, production and distribution. Australian production would proceed if the vaccine is shown to be safe and effective.
2020
AstraZeneca signs vaccine licensing deal with BioKangtai
AstraZeneca signed a licensing deal with BioKangtai to supply its AZD1222 COVID-19 vaccine candidate to China. The companies also said they would explore the possibility of producing the vaccine for other markets.
2020
AstraZeneca and Kangtai Biologics sign an exclusive China licensing framework agreement for AZD1222
AstraZeneca announced that it had signed an exclusive licensing framework agreement with Kangtai Biologics for the mainland China market, covering technology transfer and the development, production, supply and commercialization of the AZD1222 vaccine.
2020
AstraZeneca reports second-quarter results
AstraZeneca reported its second-quarter results on Thursday. Net profit was $756 million, sales rose 8% to $6.28 billion, and the company maintained its fiscal-year guidance.
2020
AstraZeneca signs European vaccine supply agreement
Italy, Germany, France and the Netherlands signed an agreement with AstraZeneca under which the company would supply its COVID-19 vaccine to EU member states if development succeeded. The agreement also provided for member states to invest and share risk.
2020
AGC Biologics acquires Colorado manufacturing facility
AGC Biologics announced that it had acquired a commercial manufacturing facility in Boulder, Colorado, previously owned by AstraZeneca.
2020
ArcherDX and AstraZeneca announce strategic collaboration
ArcherDX announced a strategic collaboration with AstraZeneca to develop personalized cancer monitoring assays supporting planned Phase 3 clinical trials for AstraZeneca's targeted immuno-oncology therapies. The agreement also allows expansion into additional disease indications and therapeutic categories.
2020
AstraZeneca donates 400,000 medical masks to Vietnam
AstraZeneca donated 400,000 medical masks to Vietnam’s Ministry of Health to support the country’s COVID-19 response.
2020
FDA approves Lynparza for first-line maintenance treatment of HRD-positive advanced ovarian cancer
The FDA approved Lynparza, in combination with bevacizumab, as first-line maintenance treatment for HRD-positive advanced ovarian cancer. AstraZeneca and MSD announced the approval.
2020
AstraZeneca agrees to manufacture and distribute Oxford vaccine
AstraZeneca agreed to manufacture and distribute a coronavirus vaccine being developed by the University of Oxford if the treatment proves effective. The partnership aims to build capacity to produce tens of millions of doses by year-end, subject to effectiveness.
2020
AstraZeneca sponsors Vidscrip COVID-19 program
AstraZeneca sponsored Vidscrip's COVID-19 program, which was made available at no cost to healthcare providers in the US during the public health emergency.
2020
Vidscrip launches COVID-19 education program
Vidscrip announced that it had launched a program providing COVID-19-specific messaging to US physicians at no cost during the public health emergency.
2020
FDA approves Imfinzi for extensive-stage SCLC
The US Food and Drug Administration approved Imfinzi, made by AstraZeneca, as first-line treatment in combination with specified chemotherapy for adults with extensive-stage small cell lung cancer.